Fate Therapeutics Inc. (FATE)’s Financial Results Comparing With Verastem Inc. (NASDAQ:VSTM)

Fate Therapeutics Inc. (NASDAQ:FATE) and Verastem Inc. (NASDAQ:VSTM) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fate Therapeutics Inc. 15 0.00 63.28M -1.23 0.00
Verastem Inc. 1 -0.39 63.32M -1.26 0.00

Table 1 demonstrates Fate Therapeutics Inc. and Verastem Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 provides Fate Therapeutics Inc. and Verastem Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Fate Therapeutics Inc. 431,062,670.30% -54.3% -39.2%
Verastem Inc. 5,590,676,319.97% -80% -40.8%

Volatility & Risk

Fate Therapeutics Inc. has a 1.62 beta, while its volatility is 62.00%, thus making it more volatile than Standard & Poor’s 500. Competitively, Verastem Inc.’s 191.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.91 beta.


The Current Ratio and Quick Ratio of Fate Therapeutics Inc. are 6.4 and 6.4 respectively. Its competitor Verastem Inc.’s Current Ratio is 7.6 and its Quick Ratio is 7.6. Verastem Inc. can pay off short and long-term obligations better than Fate Therapeutics Inc.

Analyst Recommendations

In next table is given Fate Therapeutics Inc. and Verastem Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Fate Therapeutics Inc. 0 1 5 2.83
Verastem Inc. 0 0 0 0.00

$24.83 is Fate Therapeutics Inc.’s consensus target price while its potential upside is 74.86%.

Institutional and Insider Ownership

Fate Therapeutics Inc. and Verastem Inc. has shares owned by institutional investors as follows: 98.8% and 47%. Insiders owned roughly 0.9% of Fate Therapeutics Inc.’s shares. Insiders Competitively, owned 0.4% of Verastem Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Fate Therapeutics Inc. -0.23% 3.72% 35.11% 49.39% 152% 71.86%
Verastem Inc. 13.64% 6.38% -28.23% -53.42% -80.05% -55.36%

For the past year Fate Therapeutics Inc. has 71.86% stronger performance while Verastem Inc. has -55.36% weaker performance.


On 7 of the 11 factors Fate Therapeutics Inc. beats Verastem Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companyÂ’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companyÂ’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.